FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950129668> ?p ?o ?g. }

• W2950129668 abstract "Background ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha and have been shown to be structurally and functionally similar in analytical assessments. In a phase 1 clinical pharmacokinetic (PK) study both were shown to be bioequivalent for PK parameters. The final step in the demonstration of biosimilarity is a comparative phase 3 clinical trial in a representative indication Objectives The objective of this study was to evaluate the similarity of ABP 710 compared to RP with respect to efficacy and safety. Methods In this multicenter, randomized, double-blind study, the efficacy and safety of ABP 710 was compared with the RP in subjects with moderate to severe rheumatoid arthritis. Subjects were maintained on a stable 7.5 to 25 mg/week dose of methotrexate and received 3 mg/kg infusions of the investigational products (IPs) at predetermined intervals. The primary endpoint of the study was risk difference (RD) of ACR20 at week 22; secondary endpoints included DAS28-CRP and safety at week 22. The confidence intervals (CI) for RD of ACR20 were estimated using the intention-to-treat analysis set with non-responder imputation based on the subject’s randomized treatment. Clinical equivalence was evaluated by comparing the 2-sided 90% CI with the equivalence margin of (-15%, 15%) of the RD of ACR20. For change of DAS28-CRP at week 22 from baseline, the CI of the mean difference was estimated using an analysis of covariance model with relevant baseline values and stratification factors as covariates. Results Of the 558 randomized subjects, 556 were treated (ABP 710 n=278; RP n=278). For ACR20, the RD was 9.3% and the lower bound of the 90% CI (2.67%, 15.96%) was within the pre-specified criteria, thus confirming non-inferiority; the upper bound slightly exceeded the pre-specified criteria such that superiority cannot be ruled out statistically. In post-hoc analysis when the impact of random imbalance in baseline demographic and disease characteristic between the 2 treatment arms was adjusted, the RD was reduced to 7.18% and the 90% CI was narrowed to (0.75%, 13.62%). Results of change of DAS28-CRP at week 22 showed a difference in mean change from baseline of -0.01 with 90% CI of (-0.20, 0.17). Since this difference is less than the suggested EULAR threshold of 0.6 for clinically meaningful difference, the result supports both non-inferiority and non-superiority. Through week 22, percentage of subjects reporting any serious adverse events was 4.1 (ABP 710=3.2; RP=5.0) and the binding/neutralizing antibody positive post-baseline in subjects were 58.9/19.4 (ABP 710=57.1/18.0; RP=60.6/20.8). Conclusion The results of this study indicate that ABP 710 is similar to the RP. Although we were unable to statistically confirm non-superiority, post-hoc analysis is supportive of non-superiority. The DAS28-CRP difference of less than 0.6 is believed to not be clinically meaningful. These efficacy and safety results support similarity between ABP 710 and infliximab RP. Acknowledgement Sonya Lehto and Monica Ramchandani for medical writing. Study investigators and patients Disclosure of Interests Mark C. Genovese Grant/research support from: Sanofi/Genzyme, Genentech/Roche, RPharm, Consultant for: Sanofi/Genzyme, Genentech/Roche, RPharm, Juan Sanchez-Burson Speakers bureau: Lilly, Janssen, Pfizer, MyungShin Oh Shareholder of: Amgen, Employee of: Amgen, eva Balazs Grant/research support from: Celltrion, Inc., Consultant for: Merck and Amgen, Jeffrey Neal Consultant for: Investigator Amgen, Gary Fanjiang Shareholder of: Amgen, Employee of: Amgen, Stanley Cohen Grant/research support from: AbbVie, Amgen Inc., AstraZeneca, Biogen-IDEC, Bristol Meyer Squibb, Genentech, Janssen, Eli Lilly, Novartis, Pfizer, Merck, and Roche, Consultant for: Abbvie, Amgen, AstraZeneca, Biogen-IDEC, Bristol Meyer Squibb, Genentech, Janssen, Lilly, Novartis Pfizer, Merck and Roche" @default.
• W2950129668 created "2019-06-27" @default.
• W2950129668 creator A5002599466 @default.
• W2950129668 creator A5003819213 @default.
• W2950129668 creator A5042465472 @default.
• W2950129668 creator A5057538503 @default.
• W2950129668 creator A5064943069 @default.
• W2950129668 creator A5075001511 @default.
• W2950129668 creator A5078338953 @default.
• W2950129668 date "2019-06-01" @default.
• W2950129668 modified "2023-09-28" @default.
• W2950129668 title "AB0377 CLINICAL SIMILARITY OF ABP 710 WITH INFLIXIMAB (REFERENCE PRODUCT) IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS" @default.
• W2950129668 doi "https://doi.org/10.1136/annrheumdis-2019-eular.4928" @default.
• W2950129668 hasPublicationYear "2019" @default.
• W2950129668 type Work @default.
• W2950129668 sameAs 2950129668 @default.
• W2950129668 citedByCount "0" @default.
• W2950129668 crossrefType "proceedings-article" @default.
• W2950129668 hasAuthorship W2950129668A5002599466 @default.
• W2950129668 hasAuthorship W2950129668A5003819213 @default.
• W2950129668 hasAuthorship W2950129668A5042465472 @default.
• W2950129668 hasAuthorship W2950129668A5057538503 @default.
• W2950129668 hasAuthorship W2950129668A5064943069 @default.
• W2950129668 hasAuthorship W2950129668A5075001511 @default.
• W2950129668 hasAuthorship W2950129668A5078338953 @default.
• W2950129668 hasBestOaLocation W29501296681 @default.
• W2950129668 hasConcept C112705442 @default.
• W2950129668 hasConcept C126322002 @default.
• W2950129668 hasConcept C168563851 @default.
• W2950129668 hasConcept C17991360 @default.
• W2950129668 hasConcept C197934379 @default.
• W2950129668 hasConcept C203092338 @default.
• W2950129668 hasConcept C2777138892 @default.
• W2950129668 hasConcept C2777575956 @default.
• W2950129668 hasConcept C42404028 @default.
• W2950129668 hasConcept C71924100 @default.
• W2950129668 hasConcept C98274493 @default.
• W2950129668 hasConceptScore W2950129668C112705442 @default.
• W2950129668 hasConceptScore W2950129668C126322002 @default.
• W2950129668 hasConceptScore W2950129668C168563851 @default.
• W2950129668 hasConceptScore W2950129668C17991360 @default.
• W2950129668 hasConceptScore W2950129668C197934379 @default.
• W2950129668 hasConceptScore W2950129668C203092338 @default.
• W2950129668 hasConceptScore W2950129668C2777138892 @default.
• W2950129668 hasConceptScore W2950129668C2777575956 @default.
• W2950129668 hasConceptScore W2950129668C42404028 @default.
• W2950129668 hasConceptScore W2950129668C71924100 @default.
• W2950129668 hasConceptScore W2950129668C98274493 @default.
• W2950129668 hasLocation W29501296681 @default.
• W2950129668 hasOpenAccess W2950129668 @default.
• W2950129668 hasPrimaryLocation W29501296681 @default.
• W2950129668 isParatext "false" @default.
• W2950129668 isRetracted "false" @default.
• W2950129668 magId "2950129668" @default.
• W2950129668 workType "article" @default.